Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 4/20 | 0.47 |
| ▸ | JAK1 | P23458 | 4/20 | 0.47 |
| ▸ | TYK2 | P29597 | 3/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL983761 | 0.90 | JAK2 (0.49) | GRIN2BSMN1; SMN2CYP2C19JAK2JAK1 | |
| SCHEMBL986956 | 0.85 | GRIN2B (0.47) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL2307512 | 0.80 | GRIN2B (0.72) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL2709675 | 0.77 | GRIN2B (0.56) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL2709670 | 0.77 | GRIN2B (0.56) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL171605 | 0.77 | SMN1; SMN2 (0.58) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL986440 | 0.76 | JAK2 (0.47) | GRIN2BSMN1; SMN2CYP2C19JAK2JAK1 | |
| SCHEMBL2711762 | 0.75 | GRIN2B (0.54) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL2711765 | 0.75 | USP2 (0.54) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A | |
| SCHEMBL9977252 | 0.74 | SMN1; SMN2 (0.54) | GRIN2BSMN1; SMN2CYP2C19NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265609-B1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. | 2011-01-06 | — | — | US | disclosed |
| EP-2265609-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111277-A9 | IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009111277-A1 | IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003809-A1 | IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS | BRAF, RAF1, ARAF | GRIN2B 4252/4885SMN1; SMN2 2594/4885CYP2C19 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.